Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population

NCT01763047 | Completed Results

• 1 other identifier: CR-5357
• Study Type: interventional
• Target: 298
• Locations: 1 country
• Sites: 19

Brief Summary

The objective of this study is to evaluate the performance of a novel multifocal lens system.

Conditions

Presbyopia

Outcome Measures

Primary Outcomes (6)

• Binocular Distance Visual Acuity (LogMAR)

  Distance time controlled LogMAR Visual Acuity was carried out binocularly with high luminance and high contrast, at 4m under 250 cd/m\^2. The test was presented under the condition High luminance (250 cd/m\^2) High Contrast (90%)

  8-12 days post wear

• Binocular Near Visual Acuity (logMAR)

  Near time controlled LogMAR Visual Acuity was carried out binocularly using High lumiance and High Contrast, at 40cm under 250 cd/m\^2. The test was presented under the condition High Luminance (250cd/m\^2) High Contrast (90%).

  8-12 days post wear

• Percentage of Eyes With Corneal Staining Grade 3 or Higher

  Corneal staining was evaluated in 5 corneal regions (Central, Inferior, Nasal, Temporal and Superior) using Sodium Fluorescein strips. The Fluorescien strip was lightly placed on the subject's inferior palpebral conjunctiva. The corneal Staining was graded using the scale Grade 0: No Staining, Grade 1: Trace(Minimal superficial staining or stippling), Grade 2: Mild (Regional or diffuse punctate staining), Grade 3:Moderate(Significant dense coalesced staining, corneal abrasion or foreign body tracks.), Grade 4 Severe(Severe abrasions greater than 2 mm in diameter, ulcerations, epithelial loss, or full thickness abrasion.). The data was dichotomized into two group subjects with grade 3 or higher and those subjects with less than Grade 3 for the maximum grade of corneal staining across all 5 regions.

  8-12 days post wear

• Percentage of Eyes With Limbal Conjunctival Redness Grade 3 or Higher

  The Limbus refers to the 1 to 2mm wide zone of conjunctiva and underlying tissue adjacent to where the cornea joins the sclera. Limbal Conjuctival Redness was graded in 4 regions (Nasal, Temporal, Inferior and Superior) using the Efron Grading Scale in 1 unit increments. Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4: Severe. The data was dichotomized into two group subjects with grade 3 or higher Limbal Conjuctival Redness, and those subjects with less than Grade 3 for the maximum grade of all 4 regions.

  8-12 days post wear

• Percentage of Eyes With Bulbar Conjunctival Redness Grade 3 or Higher

  Bulbar Conjunctival Injection was assessed in 4 regions (Nasal, Temporal, Inferior and Superior) using an Efron Grading scale by 1 unit increments. Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4:Severe. The data was dichotomized into two group subjects with grade 3 or higher Conjunctival injection, and those subjects with less than Grade 3 for the maximum grade of all 4 regions.

  8-12 days post wear

• CLUE Overall Quality of Vision Using the Contact Lens User Experience (CLUE)TM Questionnaire

  CLUE Overall Quality of Vision is assessed using the Contact Lens User Experience (CLUE)TM questionnaire. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).

  8-12 days post wear

Study Arms (2)

etafilcon A/lotrafilcon B

ACTIVE COMPARATOR

Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.

Device: etafilcon A; Device: lotrafilcon B

lotrafilcon B/etafilcon A

ACTIVE COMPARATOR

Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.

Device: etafilcon A; Device: lotrafilcon B

Interventions

etafilcon A DEVICE

To be worn in a daily wear modality for a minimum of 6 hours per day.

etafilcon A/lotrafilcon B; lotrafilcon B/etafilcon A

lotrafilcon B DEVICE

Lenses will be worn in a reuseable modality; cleaned and disinfected each night.

Also known as: AirOptix Aqua Multifocal

etafilcon A/lotrafilcon B; lotrafilcon B/etafilcon A

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
• Subjects must appear able and willing to adhere to the instructions set forth in the clinical protocol.
• Subjects must be between 40 and 70 years of age.
• Subjects' spherical equivalent distance refraction must be in the range of -3.75 to +3.75 in each eye.
• Subjects' refractive cylinder must be less than or equal to 0.75D in each eye.
• Subjects' ADD power must be in the range of +0.75 to +2.50D in each eye.
• Subjects' must have the best corrected visual acuity of 20/20-3 or better in each eye.
• Subjects' should own a wearable pair of spectacles.
• Subjects' must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month or more duration).
• Subjects' must respond positively to at least on symptom on the "Presbyopis Symptoms Questionnaire" or already be wearing a presbyopic contact lens correction (e.g. reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.).

You may not qualify if:

• Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
• Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
• Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
• Any previous intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.)
• Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) which may contraindicate contact lens wear.
• Any ocular infection.
• Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
• History of binocular vision abnormality or strabismus.
• Any infectious disease (e.g. hepatitis, tuberculosis) or contagious immunosuppressive disease (e.g. HIV).
• History of diabetes.
• Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (19)

Unknown Facility

Mission Viejo, California, United States

Location

RPS

Jacksonville, Florida, United States

Location

Unknown Facility

Jacksonville, Florida, United States

Location

Unknown Facility

Saint Augustine, Florida, United States

Location

Unknown Facility

Tallahassee, Florida, United States

Location

Unknown Facility

Winter Park, Florida, United States

Location

Unknown Facility

Roswell, Georgia, United States

Location

Unknown Facility

Lutherville, Maryland, United States

Location

Unknown Facility

Closter, New Jersey, United States

Location

Unknown Facility

New York, New York, United States

Location

Unknown Facility

Denver, North Carolina, United States

Location

Unknown Facility

Athens, Ohio, United States

Location

Unknown Facility

Kingston, Pennsylvania, United States

Location

Unknown Facility

Warwick, Rhode Island, United States

Location

Unknown Facility

Memphis, Tennessee, United States

Location

Unknown Facility

Amarillo, Texas, United States

Location

Unknown Facility

Tyler, Texas, United States

Location

Unknown Facility

Salt Lake City, Utah, United States

Location

Unknown Facility

Salem, Virginia, United States

Location

MeSH Terms

Conditions

Presbyopia

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Results Point of Contact

• Title: Thomas R. Karkkainen, OD., M.S., F.A.A.O- Senior Principal Research Optometrist
• Organization: Johnson & Johnson Vision Care Inc.

TKarkkai@its.jnj.com

904-443-3500

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2012
• First Posted: January 8, 2013
• Study Start: November 1, 2012
• Primary Completion: February 1, 2013
• Study Completion: February 1, 2013
• Last Updated: June 19, 2018
• Results First Posted: June 10, 2016

Record last verified: 2016-05

Locations

US (19)